Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.52 |
| ▸ | CA1 | P00915 | 5/20 | 0.52 |
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | TYMS | P04818 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | DHFR | P00374 | 3/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL887827 | 1.00 | CA2 (0.52) | CA2CA1CA12CA9TYMS | |
| SCHEMBL14497757 | 1.00 | CA2 (0.52) | CA2CA1CA12CA9TYMS | |
| SCHEMBL8726214 | 0.95 | CA2 (0.56) | CA2CA1CA12CA9TYMS | |
| SCHEMBL6510354 | 0.92 | CA2 (0.53) | CA2CA1CA12CA9TYMS | |
| SCHEMBL9014687 | 0.87 | CA2 (0.56) | CA2CA1CA12CA9LMNA | |
| SCHEMBL1064767 | 0.87 | CA2 (0.56) | CA2CA1CA12CA9LMNA | |
| SCHEMBL7902770 | 0.87 | LMNA (0.43) | CA2CA1CA12CA9TYMS | |
| SCHEMBL2638442 | 0.85 | TYMS (0.48) | CA2CA1CA12CA9TYMS | |
| SCHEMBL8723891 | 0.82 | EGFR (0.41) | CA2CA1LMNAEGFRERBB2 | |
| SCHEMBL4652733 | 0.81 | CA2 (0.40) | CA2CA1CA12CA9TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121091-A1 | Processes of preparing asymmetric dinitrobenzamide mustard compounds, intermediate compounds useful therein and products obtained therefrom | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121091-A1 | Processes of preparing asymmetric dinitrobenzamide mustard compounds, intermediate compounds useful therein and products obtained therefrom | HRH2, HRH4, H1-2 | CA2 154/4885CA1 815/4885CA12 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.